Continuous glucose monitoring (CGM) has revolutionized diabetes management, significantly enhancing glycemic control across diverse patient populations. Recent evidence supports its effectiveness in both type 1 and type 2 diabetes management, with benefits extending beyond traditional glucose monitoring approaches. CGM has demonstrated substantial improvements in glycemic control across multiple metrics. Studies report consistent glycosylated hemoglobin reductions of 0.25%–3.0% and notable time in range improvements of 15%–34%. CGM effectively reduces hypoglycemic events, with studies reporting significant reductions in time spent in hypoglycemia. CGM also serves as an educational tool for lifestyle modification, providing real-time feedback that helps patients understand how diet and physical activity affect glucose levels. While skin-related complications remain a concern, technological advancements have addressed many initial concerns. High satisfaction rates and long-term use suggest that device-related issues are manageable with proper education and support. Despite high initial costs, CGM’s prevention of complications and hospitalizations ultimately reduces healthcare expenditures. With appropriate training and support, CGM represents a transformative technology for comprehensive diabetes care.
Citations
Citations to this article as recorded by
Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria in type 1 diabetes: A cross-sectional study Ji Yoon Kim, Seohyun Kim, Sang Ho Park, Jin A Lee, So Hyun Cho, Rosa Oh, Myunghwa Jang, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Jae Hyeon Kim, Sang-Man Jin Diabetes Research and Clinical Practice.2025; 226: 112325. CrossRef
Background This study evaluated the effects of a mobile diabetes management program called “iCareD” (College of Medicine, The Catholic University of Korea) which was integrated into the hospital’s electronic medical records system to minimize the workload of the healthcare team in the real clinical practice setting.
Methods In this retrospective observational study, we recruited 308 patients. We categorized these patients based on their compliance regarding their use of the iCareD program at home; compliance was determined through self-monitored blood glucose inputs and message subscription rates. We analyzed changes in the ABC (hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol) levels from the baseline to 12 months thereafter, based on the patients’ iCareD usage patterns.
Results The patients comprised 92 (30%) non-users, 170 (55%) poor-compliance users, and 46 (15%) good-compliance users; the ABC target achievement rate showed prominent changes in good-compliance groups from baseline to 12 months (10.9% vs. 23.9%, P<0.05), whereas no significant changes were observed for poor-compliance users and non-users (13.5% vs. 18.8%, P=0.106; 20.7% vs. 14.1%, P=0.201; respectively).
Conclusion Implementing the iCareD can improve the ABC levels of patients with diabetes with minimal efforts of the healthcare team in real clinical settings. However, the improvement of patients’ compliance concerning the use of the system without the vigorous intervention of the healthcare team needs to be solved in the future.
Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few to numerous, enabling clinicians to personalize diabetes care and treatment. Thanks to rapid growth in the field of science and medical engineering, newer treatment options are coming to the market with various advantages and disadvantages to be aware of. Therefore, clinicians should rapidly adopt new trends based on guidelines and data from many clinical trials in the field of diabetes. In the treatment of dyslipidemia, trends and guidelines are changing every year, and novel therapies are being developed. In this review, we would like to summarize the major achievements in clinical medicine in 2020 in the field of diabetes mellitus and dyslipidemia.
Citations
Citations to this article as recorded by
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes Mee Kyoung Kim, Kyungdo Han, Bongsung Kim, Jinyoung Kim, Hyuk-Sang Kwon Scientific Reports.2022;[Epub] CrossRef
Combined Effects of Obesity and Dyslipidaemia on the Prevalence of Diabetes Amongst Adults Aged ≥45 Years: Evidence from a Nationally Representative Cross-Sectional Study Simin Zhang, Donghan Sun, Xiaoyi Qian, Li Li, Wenwen Wu International Journal of Environmental Research and Public Health.2022; 19(13): 8036. CrossRef
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim Journal of Lipid and Atherosclerosis.2022; 11(3): 288. CrossRef
We live in a digital world where a variety of wearable medical devices are available. These technologies enable us to measure our health in our daily lives. It is increasingly possible to manage our own health directly through data gathered from these wearable devices. Likewise, healthcare professionals have also been able to indirectly monitor patients’ health. Healthcare professionals have accepted that digital technologies will play an increasingly important role in healthcare. Wearable technologies allow better collection of personal medical data, which healthcare professionals can use to improve the quality of healthcare provided to the public. The use of continuous glucose monitoring systems (CGMS) is the most representative and desirable case in the adoption of digital technology in healthcare. Using the case of CGMS and examining its use from the perspective of healthcare professionals, this paper discusses the necessary adjustments required in clinical practices. There is a need for various stakeholders, such as medical staff, patients, industry partners, and policy-makers, to utilize and harness the potential of digital technology.
Citations
Citations to this article as recorded by
A Pilot Study Examining If the Additional Use of a Continuous Glucose Monitoring Is Helpful for Glucose Control in Older Adults Kwang Joon Kim, Yang Sun Park, Eunseo Sun, Euna Jo, Jiwon Shinn, Hyeon Woo Yim, Chang Oh Kim, Hun-Sung Kim Yonsei Medical Journal.2025; 66(6): 346. CrossRef
Evolving Regulations in Telemedicine Pilot Project: Insights Into Law, Practice, and Patient Care through International Case Studies Jiwon Shinn, Yeryeon Jung, Jeong-Yeon Kim, Seongwoo Seo, Eunseol Lee, Youseok Kim, Min Jung Ko, Hun-Sung Kim Journal of Korean Medical Science.2025;[Epub] CrossRef
Managing Talent Among Healthcare Human Resource: Strategies for a New Normal Divya Aggarwal, Vijit Chaturvedi, Anandhi Ramachandran, Taniya Singh Journal of Health Management.2024; 26(2): 384. CrossRef
Current status of remote collaborative care for hypertension in medically underserved areas Seo Yeon Baik, Kyoung Min Kim, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 33. CrossRef
Using medical big data for clinical research and legal considerations for the protection of personal information: the double-edged sword Raeun Kim, Jiwon Shinn, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 8. CrossRef
Diverse perspectives on remote collaborative care for chronic disease management Seo Yeon Baik, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2024; 6(1): 26. CrossRef
Expectations and concerns regarding medical advertisements via large commercial medical platform advertising companies: a legal perspective Raeun Kim, Hakyoung Park, Jiwon Shinn, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2024; 6(2): 48. CrossRef
Ortho-digital dynamics: Exploration of advancing digital health technologies in musculoskeletal disease management Zulipikaer Maimaiti, Zhuo Li, Zhiyuan Li, Jun Fu, Chi Xu, Jiying Chen, Wei Chai, Liang Liu DIGITAL HEALTH.2024;[Epub] CrossRef
Development of a T2D App for Elderly Users: Participatory Design Study via Heuristic Evaluation and Usability Testing Zhengyang Liu, Xinran Yu Electronics.2024; 13(19): 3862. CrossRef
Patent analysis of digital sensors for continuous glucose monitoring Olena Litvinova, Magdalena Eitenberger, Aylin Bilir, Andy Wai Kan Yeung, Emil D. Parvanov, ArunSundar MohanaSundaram, Jarosław Olav Horbańczuk, Atanas G. Atanasov, Harald Willschke Frontiers in Public Health.2023;[Epub] CrossRef
Personalized Nutrition 2020: Proceedings from the American Nutrition Association’s 61st Annual Summit Victoria A. Y. Behm, Corinne L. Bush Journal of the American College of Nutrition.2021; 40(4): 397. CrossRef
Towards Telemedicine Adoption in Korea: 10 Practical Recommendations for Physicians Hun-Sung Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Perceptron: Basic Principles of Deep Neural Networks Eung-Hee Kim, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 64. CrossRef
Lack of Acceptance of Digital Healthcare in the Medical Market: Addressing Old Problems Raised by Various Clinical Professionals and Developing Possible Solutions Jong Il Park, Hwa Young Lee, Hyunah Kim, Jisan Lee, Jiwon Shinn, Hun-Sung Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Digital health and diabetes: experience from India Jothydev Kesavadev, Gopika Krishnan, Viswanathan Mohan Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub] CrossRef